Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2025-10-02

Clinical Trial Update: Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Volenrelaxin in adults with chronic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Volenrelaxin

Snippet

Sponsor: Eli Lilly and Company | Conditions: Chronic Kidney Disease | Phase 2 | Status: WITHDRAWN